SciBac

Sci Bac

Biotechnology, 1828 El Camino Real Ste 704, Burlingame, California, 94010, United States, 1-10 Employees

scibac.com

  • twitter
  • LinkedIn

Who is SCIBAC

SciBac creates rEvolutionary live biotherapeutics that treat antibiotic resistant disease while fortifying the microbiome. We improve beneficial microorganisms using our novel platform te...

Read More

map
  • 1828 El Camino Real Ste 704, Burlingame, California, 94010, United States Headquarters: 1828 El Camino Real Ste 704, Burlingame, California, 94010, United States
  • 2015 Date Founded: 2015
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8071

checked-icon Does something look wrong? Fix it. | View contact records from SCIBAC

SciBac Org Chart and Mapping

Employees

Derik Twomey

Chief Operating Officer and Co Founder

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding SciBac

Answer: SciBac's headquarters are located at 1828 El Camino Real Ste 704, Burlingame, California, 94010, United States

Answer: SciBac's official website is https://scibac.com

Answer: SciBac's revenue is Under $1 Million

Answer: SciBac's SIC: 8071

Answer: SciBac has 1-10 employees

Answer: SciBac is in Biotechnology

Answer: SciBac contact info: Phone number: Website: https://scibac.com

Answer: SciBac creates rEvolutionary live biotherapeutics that treat antibiotic resistant disease while fortifying the microbiome. We improve beneficial microorganisms using our novel platform technology that can quickly, naturally, and safely transfer useful genetic traits. The resulting microorganism has all the best traits to target a specific disease through multiple modes of action and enhance the microbiome for faster recovery and reduced risk of reinfections. By focusing on developing therapies for antibiotic resistant diseases, SciBac fills a rapidly increasing medical need. SciBacs first product targets the nations biggest antibiotic resistant threat, Clostridium difficile infection. Our microorganism strains out compete C. difficile by stopping colonization, neutralizing toxins, and directly killing the C. difficile organism. Unlike antibiotics, our product only targets C. difficile, allowing the rest of a patients microbiome to thrive, speeding up patient recovery and lowering the risk of recurrence.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access